GlassScriptPhysician profile
Heidi Dahl
NPI 1396373536
$934.97
in general payments reported to CMS, 2019-2025
11 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $67.36 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $196.62 | 2025 | Xdemvy |
| Alcon Vision LLC | $196.37 | 2024-2025 | Clareon, Rocklatan, Argos |
| Abbvie INC. | $187.66 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $124.98 | 2025 | Tecnis Iol |
| Apellis Pharmaceuticals, INC. | $64.74 | 2025 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $59.05 | 2025 | Eylea Hd |
| Mallinckrodt Hospital Products INC. | $29.60 | 2024 | Acthar |
| Sight Sciences, INC. | $20.75 | 2024 | Omni Surgical System |
| Harrow Eye, LLC | $19.44 | 2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $19.17 | 2025 | |
| Dompe US, INC. | $16.59 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Dahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.